Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 배지윤 | * |
dc.date.accessioned | 2019-08-01T16:30:11Z | - |
dc.date.available | 2019-08-01T16:30:11Z | - |
dc.date.issued | 2019 | * |
dc.identifier.issn | 0066-4804 | * |
dc.identifier.issn | 1098-6596 | * |
dc.identifier.other | OAK-24618 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/250351 | - |
dc.description.abstract | SAL200 is derived from a phage endolysin and is a novel candidate drug for the treatment of Staphylococcus aureus infection. We investigated the efficacy of the recombinant endolysin SAL200 in a lethal murine pneumonia model. Lethal pneumonia was established by intranasally administering a methicillin-susceptible (Newman) or methicillin-resistant (LAC) S. aureus strain into BALB/c mice. The mice were treated with a single intranasal administration of SAL200 or phosphate-buffered saline at 2 h after S. aureus infection. The survival rates were recorded until 60 h after the bacterial challenge. The bacterial loads in the lungs and blood, histopathology of lung tissues, and serum cytokine levels were evaluated following the S. aureus challenge. The SAL200-treated group and control group exhibited 90% to 95% and 10% to 40% survival rates, respectively. The bacterial loads in the lungs of the SAL200-treated group were significantly lower by similar to 10-fold than those of the control group as early as 1 h after treatment. Histopathologic recovery of pneumonia was observed in the SAL200-treated mice. The cytokine levels were comparable between groups. These results suggest that direct administration of SAL200 into the lungs could be a potential adjunct treatment against severe pneumonia caused by S. aureus. | * |
dc.language | English | * |
dc.publisher | AMER SOC MICROBIOLOGY | * |
dc.subject | SAL200 | * |
dc.subject | Staphylococcus aureus | * |
dc.subject | mice | * |
dc.subject | phage endolysin | * |
dc.subject | pneumonia | * |
dc.title | Efficacy of Intranasal Administration of the Recombinant Endolysin SAL200 in a Lethal Murine Staphylococcus aureus Pneumonia Model | * |
dc.type | Article | * |
dc.relation.issue | 4 | * |
dc.relation.volume | 63 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | * |
dc.identifier.doi | 10.1128/AAC.02009-18 | * |
dc.identifier.wosid | WOS:000462474100025 | * |
dc.identifier.scopusid | 2-s2.0-85063663182 | * |
dc.author.google | Bae, Ji Yun | * |
dc.author.google | Jun, Kang Il | * |
dc.author.google | Kang, Chang Kyung | * |
dc.author.google | Song, Kyoung-Ho | * |
dc.author.google | Choe, Pyoeng Gyun | * |
dc.author.google | Bang, Ji-Hwan | * |
dc.author.google | Kim, Eu Suk | * |
dc.author.google | Park, Sang Won | * |
dc.author.google | Kim, Hong Bin | * |
dc.author.google | Kim, Nam-Joong | * |
dc.author.google | Park, Wan Beom | * |
dc.author.google | Oh, Myoung-don | * |
dc.contributor.scopusid | 배지윤(57195429959) | * |
dc.date.modifydate | 20240426113129 | * |